📣 Introducing Tracenable Pro: Unlock Unlimited Data Exports & Disclosures Access.

Nuvalent Inc

Common Name
Nuvalent
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
218
Ticker
NUVL
Exchange
NASDAQ/NGS
Description
Nuvalent Inc. is a biopharmaceutical company dedicated to the innovative development of small molecule therapies for cancer treatment. The company's primary focus is on creating targeted solutions for...

Nuvalent's Financial Statements Preview

Below are the financial statements of Nuvalent, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of USD
2024
2023
2022
Operating expenses———
Research and development
-217.77a
-113.24a
-63.73a
General and administrative
-62.59a
-36.25a
-22.38a
Total operating expenses
-280.37a
-149.49a
-86.11a
Loss from operations
-280.37a
-149.49a
-86.11a
Other income (expense)———
Change in fair value of related party revenue share liability
-17.94a
0a
0a
Interest income and other income (expense), net
38.32a
23.27a
4.25a
Total other income (expense), net
20.38a
23.27a
4.25a
Loss before income taxes
-259.99a
-126.22a
-81.85a
Income tax provision
-0.76a
0a
0a
Net loss
-260.76a
-126.22a
-81.85a
Download Data

Verified Sources Behind Nuvalent’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Nuvalent’s data sources below and access millions more through our Disclosure Search.

a. Nuvalent's 10-K 2024
a. Nuvalent's 10-K 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?